4-Hydroxytamoxifen (Afimoxifene)

Name: 4-Hydroxytamoxifen (Afimoxifene)
Brand: Selleck Chemicals
SKU: S7827
Rating: 5 (10 reviews)

For research use only.

Catalog No.S7827 Synonyms: Afimoxifene

10 publications

4-Hydroxytamoxifen (Afimoxifene) Chemical Structure

CAS No. 68392-35-8

4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.

Selleck's 4-Hydroxytamoxifen (Afimoxifene) has been cited by 10 publications

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

BMC Cancer, 2021, 21(1):931

PubMed: 34407787 ( click the link to review the publication )

BMC Dev Biol, 2021, 21(1):4

PubMed: 33517884 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):26

PubMed: 33602273 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Cell Rep, 2020, 30(1):25-36

PubMed: 31914391 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01174-z

PubMed: 33257837 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28910

PubMed: 31141164 ( click the link to review the publication )

Oncogene, 2017, 36(16):2255-2264

PubMed: 27748766 ( click the link to review the publication )

1 Customer Review

CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments.

Oncogene, 2016, 36(16):2255-2264. 4-Hydroxytamoxifen (Afimoxifene) purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description

In vitro

4-OHT is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes^[1]. 4-HT activates on-target modification frequency for intein-Cas9 variants ^[3].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MCF7 cells	MWPQdo9tcW[ncnH0bY9vKGG\|c3H5			MmPMTY5pcWKrdHnvckBw\iCnc4Tyc4dmdi2\|dHnteYxifGWmIF3DSk04KGOnbHygdJJwdGmoZYLheIlwdixiSVO1NF0xNjVibl2=	MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTV2OEixO{c,QTV2OEixO\|ww[T5?
MCF7	MY\GeY5kfGmxbjDhd5NigQ>?			Mke5SYZn\WO2aY\lJIRwe2ViZn;yJHs{UF1vIHXzeJJi\GmxbDDh[4FqdnO2IIDyc4xq\mW{YYTpc44hd2ZiTVPGMVch[2WubIOsJGVEPTBiPTCwMlAxODB\|IN88UU4>	NH:zSVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5OlgyLz5{N{[5OlgyRC:jPh?=
MCF7	MlLoSpVv[3Srb36gZZN{[Xl?		MlfVOEBpenN?	NUPnbFF{UW6mdXP0bY9vKG:oIFXSZYxxcGFiZHXndoFl[XSrb36gbY4hcHWvYX6gUWNHPyClZXzsd{BqdiCyaHXuc4whemWmIH\y[YUhWlCPSTDt[YRqfW1iY3;ueIFqdmmwZzC1KUBkcGG{Y3;hcEBl\Xi2cnHuMZRz\WG2ZXSgSmJUKGmwY4XiZZRm\CCob4KgOEBpenNiYomgV3AyKGGwZDDhcpRqNUWUIILhZoJqfCCvb37vZ49tdmGuIHHueIljd2S7IHLhd4VlKGmwLXPlcIwhX2W\|dHXyckBie3OjeTygRYN1cX[rdImgQUAxNjByMEGg{txONg>?	M3jyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEi2OlI3Lz5\|MEC4OlYzPjxxYU6=
MCF7	M3;lZWZ2dmO2aX;uJIF{e2G7			NXjDWoxLTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gZYdicW6\|dDDNR2YuPyCkcnXhd5QhfHWvb4KgZ4VtdHNidYPpcochVUOILUegZZN{[XluIFXDOVAhRSByLkCwNFEzKM7:TT6=	MkTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ6MkW5N\|UoRjF{OEK1PVM2RC:jPh?=
MCF7	Mk\sRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MljKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|LDDJR\|UxKD1iMD6wNFA2KM7:TT6=	NWXvZpJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFUzQDZpPkKyOFA2Ojh4PD;hQi=>
MCF7	M{jCRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MlWxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|LDDJR\|UxKD1iMD6wNFA2OzdizszNMi=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{CxNkc,OjZ2MEewNVI9N2F-
MCF	NE\3OpBHfW6ldHnvckBie3OjeR?=			NW[1WVhJSW62YXfvcol{fCCjY4Tpeol1gSCjdDDwdo9o\XO2ZYLvcoUhemWlZYD0c5IhcW5iaIXtZY4hVUOIIHPlcIx{KGG\|c3Xzd4VlKGG\|IHXzeJJi\GmxbD3pcoR2[2WmIILlZ4VxfG:{IILld5BwdnOnLDDJR\|UxKD1iMD6wNFA4QTR\|IN88UU4>	NIW4NW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSwO\|AyOid-Mk[0NFcxOTJ:L3G+
Ishikawa endometrial cells	Mn7KSpVv[3Srb36gZZN{[Xl?			NXH0OG13SWexbnnzeEBi[3Srdnn0fUBieyCjbHvhcIlv\SCyaH;zdIhifGG\|ZTDpcoR2[3Srb36gbY4hUXOqaXvhe4Eh\W6mb33leJJq[WxiY3XscJMh[2:vcHHy[YQhfG9iRUKsJGVEPTBiPTCwMlAxODhizszNMi=>	NFG3TYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUO4NFIxQCd-MUWzPFAzODh:L3G+
MCF7	MV\GeY5kfGmxbjDhd5NigQ>?			MX7Jcohq[mm2aX;uJI9nKGW\|dILv[4VvNWmwZIXj[YQheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDNR2YuPyCkcnXhd5Qh[2GwY3XyJINmdGy\|LDDJR\|UxKD1iMD6wNFEyPyEQvF2u	M4naclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzlzNUS5OlMoRjlzNUS5OlM9N2F-
MCF7	NXfNdIZKTnWwY4Tpc44h[XO\|YYm=		NWDlUVRzOjRiaILz	NWXtT2FFSW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDld5Rzd2enbj3pcoR2[2WmIITyZY5{[3KrcITpc44heHKnaX7jeYJifGWmIH;2[ZJvcWeqdDDmc4xtd3enZDDifUBme3S{b3flckBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCyOEBpenNiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlAxOyEQvF2u	Mon3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OU[zPVgoRjJ6Mkm2N\|k5RC:jPh?=
Rosetta 2 DE3	NVHZfmNITnWwY4Tpc44h[XO\|YYm=		NImxbmoyKGi{	NF;EUVdFcXOybHHj[Y1mdnRib3[gX\|NJZS2nc4TyZYRqd2xiZoLvcUBz\WOxbXLpcoFvfCCqdX3hckBPNXSncn3pcoFtKEircz30ZYdo\WRiRWLhcJBp[SCOQlSgbIFz[m:{aX7nJGM{QDGVL1O0NVdUN0N3M{DTJI12fGGwdDDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZUAzKESHMzDjc41x\XSnboSgZ4VtdHNiYX\0[ZIhOSCqcjDifUBUWEFiYnnu[Ilv\yCjc4PhfUwhUUN3MDC9JFAvODB2IN88UU4>	Mm\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OU[zPVgoRjJ6Mkm2N\|k5RC:jPh?=
insect cells	NV;0OpRiTnWwY4Tpc44h[XO\|YYm=			MUHJcohq[mm2aX;uJI9nKG[udX;ycY9v\SCHU{Kg[5Jm\W5iYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBGWmGucHjhJIV5eHKnc4Pl[EBqdiCrboPlZ5Qh[2WubIOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNFA3OjlizszNMi=>	NWLwT2NpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N\|UzOTRpPkK4O\|M2OjF2PD;hQi=>
MCF-7-2a	NEfa[pVHfW6ldHnvckBie3OjeR?=			MYLJcohq[mm2aX;uJI9nKGW\|dILh[IlwdCCrbnT1Z4VlKGW\|dILv[4VvKHKnY3XweI9zKHS{YX7zZ5JqeHSrb37hcEBi[3SrdnH0bY9vKGmwIF3DSk04NTKjIHPlcIx{NCCLQ{WwJF0hOC5yMEeg{txONg>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZ5MkK0PUc,OTJ4N{KyOFk9N2F-
MCF7	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVW3TVVzOjRiaILz	Mln3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkCwPFUh\|ryPLh?=	M{HKOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkeyNlU3Lz5zOEK3NlI2PjxxYU6=
MCF7	MnjWSpVv[3Srb36gZZN{[Xl?			M4rSZmlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IF3DSk04KGK{ZXHzeEB1fW2xcjDj[YxteyC3c3nu[{BOS0ZvNzDhd5NigSxiSVO1NEA:KDBwMEC4OUDPxE1w	MnrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ6MkW5N\|UoRjF{OEK1PVM2RC:jPh?=
Ishikawa cells	MXfGeY5kfGmxbjDhd5NigQ>?		MmfYO\|IhcHK\|	M1XsUmFvfGGpb37pd5Qh[WO2aY\peJkh[XRiZYP0do9o\W5icnXj[ZB1d3JiYXzwbIEw[mW2YTDpckBpfW2jbjDJd4hqc2G5YTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WytYXzpcoUheGixc4DoZZRie2ViYYPzZZktKEmFNUCgQUAxNjBzIN88UU4>	M1WyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVMyLz5{OESyOlk{OTxxYU6=
insect cells	NV;MV2NjTnWwY4Tpc44h[XO\|YYm=			M4jTOmRqe3CuYXPlcYVvfCCxZjDmcJVwemW\|Y3XpckBt[WKnbHXkJIV{fHKjZHnvcEBnem:vIHj1cYFvKHKnY3;tZolv[W62IFXSZoV1[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	NHKzXJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEizOVE4Pid-MUi4N\|UyPzZ:L3G+
MCF7	M2K2bWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFXLXYE2KGSjeYO=	NHPJZYVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFUh\GG7czygTWM2OCB;IECuNFI6OSEQvF2u	NEHwNoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2OFkzQCd-MkO4OlQ6Ojh:L3G+
GT1-7	MV\GeY5kfGmxbjDhd5NigQ>?		MlWwNlAhfG9iMkSgbJJ{	NXHKZ5lpSW62YXfvcol{fCCjY4Tpeol1gSCjdDDld5Rzd2enbjDy[YNmeHSxcjDpckBud3W\|ZTDHWFEuPyClZXzsd{Bp[XKkb4Lpcoch[mW2YT3nZYxi[3Sxc3nkZZNmKHKncH;yeIVzKGenbnWgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIEG3ZoV1[S2nc4TyZYRqd2xiaX7keYNm\CC{ZYPwc45{\SCvZXHzeZJm\CCjZoTldkAzOCC2bzCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5yM{OyJO69VS5?	NUGxfFlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NFAzOzlpPkK4OFAxOjN7PD;hQi=>
insect cells	M2rsZ2Z2dmO2aX;uJIF{e2G7			MXrEbZNxdGGlZX3lcpQhd2ZiZnz1c5Jme2OnaX6gcIFj\WynZDDld5Rz[WSrb3yg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCHUnHsdIhiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigSxiSVO1NEA:KDBwMESg{txONg>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh\|NUG3Okc,OTh6M{WxO\|Y9N2F-
HEK293	NWDmSm5XTnWwY4Tpc44h[XO\|YYm=		M3PQTFMxKG2rboO=	M3vucmlvcGmkaYTpc44hd2ZiR1\QMZRi\2enZDDoeY1idiCSTFSyJIV5eHKnc4Pl[EBqdiCqdX3hckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heGixc4DoZZRq\HmuYoX0ZY5wdC2dZEndJJBzd2S3Y4Tpc44h[W[2ZYKgN\|AhdWmwczDifUBu[XO\|IIPw[YN1em:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB2NDFOwG0v	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF\|Nkm3OUc,OTlzM{[5O\|U9N2F-
HEK293	Ml;kSpVv[3Srb36gZZN{[Xl?		MYmxJIhz	M16yemFvfGGpb37pd5Qh[WO2aY\peJkh[XRicnXjc41jcW6jboSgbJVu[W5iRWLhcJBp[SCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh\XO2cnHkbY9tNWmwZIXj[YQhYU[SLX\1d4VlKFOUQ{GgZ49i[3SrdnH0c5IhemWlcoXpeI1mdnRibXXhd5Vz\WRiYX\0[ZIhOSCqcjDpckBxemW\|ZX7j[UBw\iCFb3Xs[Y51\XKjennu[UBJKGK7IFLSSXQh[XO\|YYmsJGlEPTBiPTCwMlA4KM7:TT6=	MmXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	M1\SXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYq3NkBpenN?	Mmr0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDld5Rzd2enbjDy[YNmeHSxcjDk[ZBmdmSnboSgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNFch\|ryPLh?=	NEXPTFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEizOVE4Pid-MUi4N\|UyPzZ:L3G+
MCF7	NE\ZNZJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3;lO\|czKGi{cx?=	NIL0TFhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IITyfZBidiCkbIXlJIF{e2G7LDDHTVUxKD1iMD6xNFch\|ryPLh?=	NH\xeII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ezOVgzQSd-MkO3N\|U5Ojl:L3G+
MCF7	NIPLRoJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIPp[Xk4OiCqcoO=	NVSyeYJySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGWi2mZYDlcoRmdnRiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMTFOwG0v	NFXxRlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk{OSd-Mki0NlY6OzF:L3G+
T47D	MkjNR5l1d3SxeHnjbZR6KGG\|c3H5		MVy1JIRigXN?	M3;YZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHQ1P0RiY3XscJMh[W[2ZYKgOUBl[Xm\|LDDJR\|UxKD1iMD6yNUDPxE1w	NYeyOYhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OlQ6OjhpPkKzPFY1QTJ6PD;hQi=>
Ishikawa endometrial cells	M4nkOmZ2dmO2aX;uJIF{e2G7			NWLNe5FRSW62YXfvcol{fCCjY4Tpeol1gSCjczDpcohq[mm2aX;uJI9nKDFibl2gNVcu[mW2YT3ld5Rz[WSrb3ygd5RqdXWuYYTl[EBidGujbHnu[UBxcG:\|cHjheIF{\SCrbnT1Z5Rqd25iaX6gTZNpcWujd3Gg[Y5ld22ndILpZYwh[2WubIOsJGlEPTBiPTCwMlUyKM7:TT6=	NV6xboxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWzPFAzODhpPkG1N\|gxOjB6PD;hQi=>
CV1	MXjGeY5kfGmxbjDhd5NigQ>?		NEnxWHo1PSCqcoO=	MkLRTY53\XK\|ZTDh[49vcXO2IHHjeIl3cXS7IHH0JGdCVDRvRF7BJIJqdmSrbneg[I9u[WmwLX\1d4VlKG2xdYPlJGVTWmejbX3hJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gRYZzcWOjbjDndoVmdiCvb37r[ZkhS1ZzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJJJm[2WydH;yJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDh[pRmeiB2NTDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE43KM7:TT6=	MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOEmzPVMoRjJ6MUi5N\|k{RC:jPh?=
CV1	MVnGeY5kfGmxbjDhd5NigQ>?		NHXJS3g1PSCqcoO=	MULJcpZmenOnIHHnc45qe3RiYXP0bZZqfHliYYSgS2FNPC2GTlGgZolv\GmwZzDkc41icW5vZoXz[YQhcHWvYX6gSXJT[mW2YTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h\XiycnXzd4VlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDy[YNmeHSxcjD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYX\0[ZIhPDViaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuOlUh\|ryPLh?=	M3;T[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUi5N\|k{Lz5{OEG4PVM6OzxxYU6=
HEK293	NYGxWpplTnWwY4Tpc44h[XO\|YYm=			MYLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHXzeJJw\2WwIILlcIF1\WRicnXj[ZB1d3JiZ3HtcYEh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCxMlM2KM7:TT6=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNU[4PEc,OjV\|MEW2PFg9N2F-
MCF7	MoHYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MX:0PEBpenN?	M3\OZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDlfJBz\XO\|aX7nJIV{fHKxZ3XuJJJm[2WydH;yJIlv[3WkYYTl[EB4cXSqIECuNFA{KG6PIH;mJIV{fHKjZHnvcEBidmRiMD6wNUBvVSCxZjD0[ZN1d3O2ZYLvcoUh[W[2ZYKgOFghcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XliaX6gdJJme2WwY3Wgc4YhPSViZnX0ZYwh[m:4aX7lJJNmenWvLDDHTVUxKD1iMT60NVI2PCEQvF2u	NIG4fpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWxN\|I4PSd-MkG1NVMzPzV:L3G+
MCF7	M37NNWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NIDSNog1QCCqcoO=	MnK4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHX4dJJme3Orbneg[ZN1em:pZX6gdoVk\XC2b4KgbY5kfWKjdHXkJJdqfGhiMD6wOkBvVSCxZjDld5Rz[WSrb3ygZY5lKDBwMEegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJIZmfGGuIHLveolv\SC\|ZYL1cUBidmRiToXT[ZJ2dSxiR1m1NEA:KDFwOUC1OFYh\|ryPLh?=	NInNT5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWxN\|I4PSd-MkG1NVMzPzV:L3G+
HeLa	NXu0SlRDTnWwY4Tpc44h[XO\|YYm=		MlzXOE42KGi{cx?=	M1HFbGlvcGmkaYTpc44hd2ZiRXLvcIF3cXK3czDncJlkd3C{b4TlbY4wdWG2cnn4JJBzd3SnaX6gWnA1OCCnboTyfUBqdiCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQvPSCqcoOgZoV1[S2uYXP0ZY1ie2VicnXwc5J1\XJiYYPzZZktKEmFNUCgQUAyNjl4IN88UU4>	M1TRO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK0N\|g4Lz5{OU[yOFM5PzxxYU6=
MDA-MB-231	MkPtR5l1d3SxeHnjbZR6KGG\|c3H5		NVfSe5pRPCCmYYnz	MoLMR5l1d3SxeHnjbZR6KGGpYXnud5QhTVJibnXnZZRqfmViaIXtZY4hVUSDLV3CMVI{OSClZXzsd{B1emWjdHXkJIV3\XK7IEKg[IF6eyCob4KgOEBl[Xm\|IH3lZZN2emWmIHHmeIVzKDdiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFIvPSEQvF2u	M{X0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	NX;ob48zSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MkjlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX41mfGi7bD2zTH11cHmvaXTpcoUhcW62bzDj[YxtfWyjcjDEUmEhcW5ic3XyeY0h\nKnZTDt[YRqfW1iaX6gbY4h[WK\|ZX7j[UBw\iB4LkKgeYcwdUxiUl7hd4UhOSxiSVO1NEA:KDJwNzFOwG0v	NWfKeYlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NVE1PzhpPkKyOlEyPDd6PD;hQi=>
MCF7	MoKzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUW3NkBpenN?	NYHHWWtISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyMlc6KM7:TT6=	MnfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6OU[3NFYoRjJ4OEm2O\|A3RC:jPh?=
MCF12A	NUW4VFNUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYO0PEBpenN?	M3;wT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[ZN1em:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIF3DSlEzSSClZXzsd{BqdmO3YnH0[YQhf2m2aDCxNFAhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkC3JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kBn\XSjbDDic5ZqdmVic3XyeY0h[W6mIF71V4VzfW1uIFfJOVAhRSB\|LkKzOVk1KM7:TT6=	NVz1V5A6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
MCF7	M{PJfmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3;4R\|Qh\GG7cx?=	MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCyb4PpeIl3\SCqdX3hckBOS0Z5IHPlcIx{KHS{ZXH0[YQh\X[ncomgNkBl[Xm\|IH\vdkA1KGSjeYOgcYVie3W{ZXSgZYZ1\XJiNzDkZZl{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOy5\|IN88UU4>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF12A	NWC1dHVJSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn7JOFghcHK\|	M4CwZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[ZN1em:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIF3DSlEzSSClZXzsd{BqdmO3YnH0[YQhf2m2aDCwMlAxOyCwTTDv[kBme3S{YXTpc4wh[W6mIECuNFEhdk1ib3[geIV{fG:\|dHXyc45mKGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7IHnuJJBz\XOnbnPlJI9nKDVnIH\leIFtKGKxdnnu[UB{\XK3bTygS2k2OCB;IEOuN\|EyOzFizszNMi=>	NILSd5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWxN\|I4PSd-MkG1NVMzPzV:L3G+
MCF7	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUnEUoRxPDhiaILz	NHz1fJJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOg[ZhxemW\|c3nu[{Bme3S{b3flckBz\WOncITvdkBqdmO3YnH0[YQhf2m2aDCxNFAhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkC3JI5OKG:oIITld5Rwe3Sncn;u[UBi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSCrbjDwdoV{\W6lZTDv[kBn\XSjbDDic5ZqdmVic3XyeY0h[W6mIF71V4VzfW1uIFfJOVAhRSB\|LkS2O\|M4KM7:TT6=	MnTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
MDA-MB-231	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=		NFjxbIE1KGSjeYO=	NV7VPW1GS3m2b4TvfIlkcXS7IHHnZYlve3RiRWKgcoVo[XSrdnWgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyC2cnXheIVlKGW4ZYL5JFIh\GG7czDmc5IhPCCmYYnzJI1m[XO3cnXkJJBwe3RibHHzeEBld3OnIHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnbnPlJIF{e2G7LDDJR\|UxKD1iMz61JO69VS5?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF12A	NHS0UFRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mn\1OFghcHK\|	NWrsclQ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBme3S{b3flckBz\WOncITvdk1l\W[rY3nlcpQhcHWvYX6gUWNHOTKDIHPlcIx{KGmwY4XiZZRm\CC5aYToJFAvODZibl2gc4Yh\XO2cnHkbY9tKGGwZDCwMlA4KG6PIH;mJJRme3Sxc4Tldo9v\SCjZoTldkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTDpckBxemW\|ZX7j[UBw\iCoZYThcEBjd3[rbnWgd4VzfW1iYX7kJG52W2W{dX2sJGdKPTBiPTCzMlg6ODR3IN88UU4>	NHvxZ3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWxN\|I4PSd-MkG1NVMzPzV:L3G+
MCF7	MmjBR5l1d3SxeHnjbZR6KGG\|c3H5		MXu0JIRigXN?	M4XpWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEWUIIDvd4l1cX[nIHj1cYFvKE2FRkegZ4VtdHNidILlZZRm\CCndnXyfUAzKGSjeYOg[o9zKDRiZHH5d{Bu\WG\|dYLl[EBxd3O2IHzhd5Qh\G:\|ZTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygTWM2OCB;IEOuPUDPxE1w	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF7	M4XiS2Z2dmO2aX;uJIF{e2G7			MWTJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgdJJwdGmoZYLheIlwdiCxZjDNR2YuPyClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNIUuPiCPIHPvcoNmdnS{YYTpc44hd2ZiW{PIYU0h\XO2cnHkbY9tKCiHMjmsJGlEOzBiPTC0JO69VS5?	MmHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4OU[4NUc,Ojd4OU[4NVww[T5?
MCF10A	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=		MXW0JIRigXN?	NGTyZYdEgXSxdH;4bYNqfHliYXfhbY5{fCCHUjDu[YdifGm4ZTDoeY1idiCPQ1[xNGEh[2WubIOgeJJm[XSnZDDleoVzgSB{IHThfZMh\m:{IESg[IF6eyCvZXHzeZJm\CCyb4P0JIxie3RiZH;z[UBjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFQh\|ryPLh?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF10A	MnzkR5l1d3SxeHnjbZR6KGG\|c3H5		MlfTOEBl[Xm\|	MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBGWiCwZXfheIl3\SCqdX3hckBOS0ZzMFGgZ4VtdHNidILlZZRm\CCndnXyfUAzKGSjeYOg[o9zKDRiZHH5d{Bu\WG\|dYLl[EBi\nSncjC3JIRigXNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSB2IN88UU4>	NETSTo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+
yeast cells	NEG4VlRCdnSrZYP0do9o\W6rYzDhd5NigQ>?			MYjBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCjdDDld5Rzd2enbjDy[YNmeHSxcjDhcJBp[SCneIDy[ZN{\WRiaX6gfYVie3RiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kAyPy2kZYThMYV{fHKjZHnvcE1qdmS3Y3XkJIJmfGFvZ3HsZYN1d3OrZHHz[UBi[3Srdnn0fUBjgSC2d3:gbJljemmmIHHzd4F6NCCLQ{WwJF0hPC52IN88UU4>	NIG5TIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS0NVA5Pid-MU[0OFExQDZ:L3G+
NCI-ADR-RES	NXLZco9VSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmTDOFghcHK\|	MmW5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDld5Rzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iTlPJMWFFWi2URWOgZ4VtdHNiaX7jeYJifGWmIIfpeIghOC5yMEOgcm0hd2ZiZYP0doFlcW:uIHHu[EAxNjBzIH7NJI9nKHSnc4Tvd5Rmem:wZTDh[pRmeiB2ODDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUBqdiCycnXz[Y5k\SCxZjC1KUBn\XSjbDDic5ZqdmVic3XyeY0tKEeLNUCgQUA1NjR4Nki0JO69VS5?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzM{K3OUc,OjF3MUOyO\|U9N2F-
BT-20	MnL6SpVv[3Srb36gZZN{[Xl?	M{PGZlExKM7:TR?=		MWDJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgdJJwdGmoZYLheIlwdiCxZjDCWE0zOCClZXzsd{BqdiCycnXz[Y5k\SCxZjDUVGUh[XRiMUDlMVUhVSClb37j[Y51emG2aX;uMEBKSzNyIE2gOE45KM7:TT6=	M4PhOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5Nkm2PFEoRjJ5Nkm2PFE9N2F-
Calu-1	MV7GeY5kfGmxbjDhd5NigQ>?		MYmzNEBucW6\|	MmXVTY5pcWKrdHnvckBw\iCSTFSxJIlvKGi3bXHuJGNidHVvMTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBxcG:\|cHjheIllgWykdYThco9tNVumOW2gdJJw\HWldHnvckBi\nSncjCzNEBucW6\|IHL5JI1ie3Nic4DlZ5Rzd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFQvQCEQvF2u	M3PYdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUO2PVc2Lz5zOUGzOlk4PTxxYU6=
MCF7	NEDM[XlHfW6ldHnvckBie3OjeR?=			NVrDdoRQSW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIILlZ4VxfG:{IHnuJIh2dWGwIF3DSlch[2WubIOsJGlEPTBiPTC0Mlg6Pzd7IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{CxNkc,OjZ2MEewNVI9N2F-
MDA-MB-231	MWHBcpRq[2GwY3XyJIF{e2G7		M3KweVQ5KGi{cx?=	M4WwWGFvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDFVk1xd3OrdHn2[UBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTC1MlQh\|ryPLh?=	NVPNbVZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYyPDVpPkK0PVQ3OTR3PD;hQi=>
MCF-7	MVnDfZRwfG:6aXPpeJkh[XO\|YYm=			M1j5ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KE2FRj23JINmdGy\|IHnuJJRp\SCjYoPlcoNmKG:oIEGgeW0hTTJiKHXzeJJi\GmxbDmsJGN6fG:2b4jpZ4l1gSB;IE[g{txONg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86ODh7M{OyK\|46ODh7M{OyQE9iRg>?
NCI-ADR-RES	M2HxXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYG0PEBpenN?	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{LXTl[olkcWWwdDDoeY1idiCQQ1mtRWRTNVKHUzDj[YxteyCrbnP1ZoF1\WRid3n0bEAxNjB4IH7NJI9nKGW\|dILh[IlwdCCjbnSgNE4xPyCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiZnX0ZYwh[m:4aX7lJJNmenWvIHHu[EBPfVOncoXtMEBIUTVyIE2gOk4yPjV7NTFOwG0v	M2HCXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
AU565	M2rZTWFvfGmlYX7j[ZIh[XO\|YYm=		MnvvOFghcHK\|	NVrOdXdWSW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNW6nZ3H0bZZmKEGXNU[1JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB4LkKg{txONg>?	MorsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[xOFUoRjJ2OUS2NVQ2RC:jPh?=
MCF7L	MYnBcpRq[2GwY3XyJIF{e2G7		NYrCV4hXPDhiaILz	Mlz0RY51cWOjbnPldkBi\2GrboP0JIh2dWGwIFXSMZBwe2m2aY\lJG1ETjeOIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA3NjNizszNMi=>	M{OybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NVQ2Lz5{NEm0OlE1PTxxYU6=
SKOV3-MDR1-M6/6	MWnBcpRq[2GwY3XyJIF{e2G7		MVq0PEBpenN?	M1PZPWFvfGmlYX7j[ZIh[WejaX7zeEBpfW2jbjDTT29XOy2PRGKxMW03NzZiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvPDlizszNMi=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
MCF7	NX7aSW94SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3rB[VI1KGi{cx?=	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDdwMjFOwG0v	MljuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzOEmwOVUoRjJ2MUi5NFU2RC:jPh?=
SKOV3	MWPBcpRq[2GwY3XyJIF{e2G7		NYj4[YxCPDhiaILz	NIXB[ZFCdnSrY3HuZ4VzKGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegVE1oeCCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPy52NjFOwG0v	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
PC3	M1TNZ2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWXKeIxYPDhiaILz	M3jG[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgZY5lem:pZX6gdoVk\XC2b4Kt[IVncWOrZX70JIh2dWGwIGDDN{Bk\WyuczDpcoN2[mG2ZXSge4l1cCByLk[gcm0hd2ZiZYP0doFlcW:uIHHu[EAxNjdibl2gc4YhfGW\|dH;zeIVzd26nIHHmeIVzKDR6IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyIE2gO{42QDV5ODFOwG0v	NVXYeZNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NVMzPzVpPkKxOVE{Ojd3PD;hQi=>
NCI-ADR-RES	NXHBfo5RSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUP6PIhUPDhiaILz	Ml7SRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDld5Rzd2enbjDy[YNmeHSxcj3k[YZq[2mnboSgbJVu[W5iTlPJMWFFWi2URWOgZ4VtdHNiaX7jeYJifGWmIIfpeIghOTByIH7NJI9nKGW\|dILh[IlwdCCjbnSgNE4xPyCwTTDv[kB1\XO2b4P0[ZJwdmViYX\0[ZIhPDhiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiZnX0ZYwh[m:4aX7lJJNmenWvIHHu[EBPfVOncoXtMEBIUTVyIE2gO{44PjJ2NzFOwG0v	M2TvV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF-7	NXXkRoNOS3m2b4TvfIlkcXS7IHHzd4F6			NXLNUGtzS3m2b4P0ZZRq[2m2eTDh[4FqdnO2IF3DSk04KGOnbHzzJIlvKHSqZTDwdoV{\W6lZTDv[kAyKHWPb3zhdkBGOiBqZYP0doFlcW:uKTygTWM2OCB;IEig{txONg>?	M{LiRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzlyOEmzN\|IoRjlyOEmzN\|I9N2F-
LNCAP	NVHBelJGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NH\2RY81QCCqcoO=	M1rJdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOg[ZhxemW\|c3nu[{BidmS{b3flckBz\WOncITvdkBqdmO3YnH0[YQhf2m2aDCwMlYhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hQC5\|MUe2OEDPxE1w	MlvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MUOyO\|UoRjJzNUGzNlc2RC:jPh?=
MCF7	MlnNRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYm1JIRigXN?	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KFeVVD24JIF{e2G7LDDJR\|UxKD1iOD65JO69VS5?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZzNEGxPEc,OjV4MUSxNVg9N2F-
MCF7	MmHnRY51cWOjbnPldkBie3OjeR?=		M1HiU\|Q5KGi{cx?=	NUXNXlY{SW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDlwMjFOwG0v	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkG0OUc,OjR7NE[xOFU9N2F-
MCF-7	M1fMRWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MlXFR5l1d3SxeHnjbZR6KGGpYXnud5QhVUOILUegZ4VtdHNiaX6gdJJme2WwY3Wgc4YhOSC3TTDFNkAp\XO2cnHkbY9tMSxiQ4n0c5RwgGmlaYT5JF0hQS52IN88UU4>	Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTB6OUOzNkc,QTB6OUOzNlww[T5?
MDA-MB-231	M1\sfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYC0TpR{OjRiaILz	NIrIbGRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFyLkSg{txONg>?	NIXaUVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4PVA2PSd-MkSxPFkxPTV:L3G+
MDA-MB-453	M2nL[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVG4[WxpPzJiaILz	M1HsbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTR3MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTBwNDFOwG0v	NIXnbmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWwOlU5Oid-Mki1NFY2QDJ:L3G+
DU145	NX36Z3V2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmW1OFghcHK\|	NHTGNIdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIFv\HKxZ3XuJJJm[2WydH;yMYRm\mmlaXXueEBpfW2jbjDEWVE1PSClZXzsd{BqdmO3YnH0[YQhf2m2aDCwMlYhdk1ib3[g[ZN1emGmaX;sJIFv\CByLkegcm0hd2ZidHXzeI9{fGW{b37lJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hOTBwN{G1NkDPxE1w	M2XJTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUGzNlc2Lz5{MUWxN\|I4PTxxYU6=
MCF7	M3LBNGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoXsOFghcHK\|	M3\OUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE{NjZizszNMi=>	M4L6SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkG4OVk2Lz5{NU[xPFU6PTxxYU6=
Vero	MmH2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NY\SZYl5PzJiaILz	M{DQOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgZYZzcWOjbjDndoVmdiCvb37r[ZkhXmW{bzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxOU4yKM7:TT6=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7M{K2PUc,OjV7OUOyOlk9N2F-
DU145	M3zJVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2rjUVczKGi{cx?=	NUj4fpRVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzNT6zJO69VS5?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7M{K2PUc,OjV7OUOyOlk9N2F-
MCF7	M3jnUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGj4[\|Q4OiCqcoO=	NXzHc2JISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxOU43KM7:TT6=	NWHWZZpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFY2QDJpPkK4OVA3PTh{PD;hQi=>
MCF7	MmriRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NV\iZ3lCPzJiaILz	NHjiW\|lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTVwNjFOwG0v	NV3jNJdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PVMzPjlpPkK1PVk{OjZ7PD;hQi=>
MDA-MB-231	M4DqdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXvORZdPPzJiaILz	MlnxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzOC5zIN88UU4>	MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3ME[1PFIoRjJ6NUC2OVgzRC:jPh?=
MCF7	MoO1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MkHiNE43OjVibl2=	M2rtPVI1KGi{cx?=	MlTqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHH0JFAvPjJ3IH7NJIFnfGW{IEK0JIhzeyCkeTDNWHMh[XO\|YYm=	M3nLeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkeyNlU3Lz5zOEK3NlI2PjxxYU6=
MCF7	M{XpT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7	MorhNE43OjVidH:gNVAhdk1?	NFvSR3QzPCCqcoO=	M{DndWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDheEA,OC54MkWgeI8hOTBibl2gZYZ1\XJiMkSgbJJ{KGK7IF3UV{Bie3OjeR?=	M3;lNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkeyNlU3Lz5zOEK3NlI2PjxxYU6=
MCF7:WS8	M{nSUmZ2dmO2aX;uJIF{e2G7			NUXwd\|N4SWO2aY\heIlwdiCxZjDoeY1idiCHUjDpckBpfW2jbjDNR2Y4QleVODDj[YxteyCneIDy[ZN{cW6pIHXzeJJw\2WwIILld5BwdnOrdnWg[YxmdWWwdDDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	NF34d4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOzOFM3QCd-MkCzN\|Q{Pjh:L3G+
MCF7:WS8	NYjDTm9tSW62aXXzeJJw\2WwaXOgZZN{[Xl?	MYWxJJVO	MWG3JIRigXN?	MnzlRY51cWW\|dILv[4VvcWNiYXP0bZZqfHliaX6gbJVu[W5iRWLhcJBp[SCneIDy[ZN{cW6pIF3DSlc7X1N6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh\XO2cnHkbY9tNWmwZIXj[YQheHKxbHnm[ZJifGmxbjDheEAyKHWPIHHmeIVzKDdiZHH5dy=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN\|NEO2PEc,OjB\|M{SzOlg9N2F-
MCF7	MnOwRY51cWW\|dILv[4VvcWNiYYPzZZk>			NX7COIxvSW62aXXzeJJw\2WwaXOgZYN1cX[rdImgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIV{fHKjZHnvcE1{fGmvdXzheIVlKHC{b3zhZ5RqdiCpZX7lJIV5eHKnc4Ppc44>	NUHzXXA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzN\|Q{PjhpPkKwN\|M1OzZ6PD;hQi=>
MCF7	MWXBcpRq\XO2cn;n[Y5q[yCjc4PhfS=>			MYjBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZYP0doFlcW:uLYP0bY12dGG2ZXSgdJJwdGmoZYLheIlwdg>?	NUHhVlJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzN\|Q{PjhpPkKwN\|M1OzZ6PD;hQi=>
T47D:C:4:2	M{DiO2Z2dmO2aX;uJIF{e2G7			Mlr0SZN1em:pZX7pZ{Bi[3Srdnn0fUBifCC5aXzkJJR6eGViRWKgZYxxcGFiZYjwdoV{e2WmIHnuJHQ1P0R8Q{q0PlIh[2WubIOgZ49mgHC{ZYPzbY5oKGW\|dILv[4VvKHKnc4DvcpNmKGWuZX3lcpQh[nliZIXlcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	NViyW4hFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzN\|Q{PjhpPkKwN\|M1OzZ6PD;hQi=>
MDA-MB-231	NX;ZRWtqS3m2b4TvfIlkcXS7IHHzd4F6		MlLVN{Bl[Xm\|	MlO1R5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KG2rY4LveIl1\XJiYYPzZZk>	MlrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3OUi1OVUoRjJyNUm4OVU2RC:jPh?=
T47D:C:4:2	M2LFXGZ2dmO2aX;uJIF{e2G7			Mk\USZN1em:pZX7pZ{Bi[3Srdnn0fUBifCC5aXzkJJR6eGViRWKgZYxxcGFiREO1NWchdXW2YX70JIV5eHKnc4Pl[EBqdiCWNEfEPmM7PDp{IHPlcIx{KGOxZYjwdoV{e2mwZzDld5Rzd2enbjDy[ZNxd26\|ZTDlcIVu\W62IHL5JIR2\WxibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN\|NEO2PEc,OjB\|M{SzOlg9N2F-
MCF7	MmWxSpVv[3Srb36gZZN{[Xl?	M3\yd\|Eh\|ryP	M2\Z[\|Yh\GG7cx?=	MUHEdpVoKHWydHHr[UBqdiCqdX3hckBOS0Z5IHPlcIx{KGG2IEGwK{03KE1iYX\0[ZIhPiCmYYnzJIJ6KEiSTFOtUXMwVVNiYX7hcJl{cXN?	M2rXeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OE[0PVI5Lz5{M{i2OFkzQDxxYU6=
MCF7	MYrGeY5kfGmxbjDhd5NigQ>?	MUCxNEB2VQ>?	NYexPIlMPiCqcoO=	MYHVdJJm\3WuYYTpc44hd2ZiRWLhcJBp[SCycn;0[YlvKGyndnXsd{BqdiCqdX3hckBOS0Z5IHPlcIx{KGG2IEGwJJVOKGGodHXyJFYhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	MkG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{K2N\|AoRjJ2M{OyOlMxRC:jPh?=
MCF7:WS8	MlfDSpVv[3Srb36gZZN{[Xl?	Mo\zNUDPxE1?	NEfPOWU1QCCqcoO=	M{DSemFod26rc4SgZYN1cX[rdImgZZQhTVJiaX6gbJVu[W5iTVPGO\|pYWzhiY3XscJMh[XO\|ZYPz[YQh[XNicGOyJIdmdmViZYjwdoV{e2mxbjDheEAyOCdvNjDNJIFnfGW{IES4JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN?	M1L2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1NVk6Lz5{NEiwOVE6QTxxYU6=
MCF7:WS8	MUXGeY5kfGmxbjDhd5NigQ>?	MkjNNUDPxE1?	NG\Ed3U1QCCqcoO=	NEnkc3pC\2:waYP0JIFkfGm4aYT5JIF1KEWUIHnuJIh2dWGwIF3DSlc7X1N6IHPlcIx{KGG\|c3Xzd4VlKGG\|IFfSSWIyKGenbnWg[ZhxemW\|c3nvckBifCBzMDetOkBOKGGodHXyJFQ5KGi{czDifUBTXC2SQ2KgZY5idHm\|aYO=	MknrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEWxPVkoRjJ2OEC1NVk6RC:jPh?=
GH3	NUHWcVVpTnWwY4Tpc44h[XO\|YYm=	M4LKbVEh\|ryP	MWm0PEBpenN?	M{\WUGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTZiTTDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{	NGHxNYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVE6QSd-MkS4NFUyQTl:L3G+
GH3	NEXuSItHfW6ldHnvckBie3OjeR?=	NFnTXJcxNjFibl2geI8hOSEQvF2=	Mo\LOFghcHK\|	M2nCOmFvfGGpb37pd5Qh[WO2aY\peJkh[XRiRWKgbY4hemG2IFfIN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHXzeJJi\GmxbD3pcoR2[2WmIIDyc4xi[3SrbjDn[Y5mKGW6cILld5Nqd25iYYSgNVAoNTFyIITvJFExLy14IF2gZYZ1\XJiNEigbJJ{KGK7IGLUMXBEWiCjbnHsfZNqew>?	NEPVbnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVE6QSd-MkS4NFUyQTl:L3G+
MCF7	NU\tOnRoSW62aXPhcoNmeiCjc4PhfS=>	M1SyXFI2OCC2bzC1NFAhdk1?	MX61JIRigXN?	NYDsOoI6SW62aXPhcoNmeiCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCnc4TyZYRqd2xvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlUxKHSxIEWwNEBvVSCjZoTldkA2KGSjeYO=	MorWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[xOFUoRjJ2OUS2NVQ2RC:jPh?=
MCF7	Mo\KSpVv[3Srb36gZZN{[Xl?	M2WwVlUhfU1?	NWPlbZZzOjRiaILz	NWWyfGhFSW62YXfvcol{fCCjY4Tpeol1gSCjdDDFVoFteGijIHnuJIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gUXlEKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5OE[wPUc,OzByN{i2NFk9N2F-
MCF7	M2m0Z2Z2dmO2aX;uJIF{e2G7	MUK1JJVO	M3LTbVI1KGi{cx?=	NH7jUIZCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDUSmYyKG2UTlGg[ZhxemW\|c3nvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDRTWF7d2xicnXh[4VvfCCkYYPl[EBTXC2zUFPSJIFv[Wy7c3nz	M1L0PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	MoPKSpVv[3Srb36gZZN{[Xl?	NVfFNFk1PSC3TR?=	MnTuNlQhcHK\|	MmW4RY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiR2LFRlEhdVKQQTDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGHJRZpwdCC{ZXHn[Y51KGKjc3XkJHJVNXGSQ2KgZY5idHm\|aYO=	NYHz[npMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	NH\NTplHfW6ldHnvckBie3OjeR?=	Ml22OUB2VQ>?	M{HPXFI1KGi{cx?=	NGjXWYtCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDNXWJNOiCvUl7BJIV5eHKnc4Ppc44h[XRiNTD1UUBi\nSncjCyOEBpenNiYomgVWlCgm:uIILlZYdmdnRiYnHz[YQhWlRvcWDDVkBidmGueYPpdy=>	M4HrR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	M{PiZWZ2dmO2aX;uJIF{e2G7	NEfhO2o2KHWP	NF\3eXYzPCCqcoO=	Mm[2RY51[WexbnnzeEBi[3Srdnn0fUBifCCHUnHsdIhiKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiQ1POSFEhdVKQQTDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGHJRZpwdCC{ZXHn[Y51KGKjc3XkJHJVNXGSQ2KgZY5idHm\|aYO=	NWe1WXBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|g3ODlpPkOwNFc5PjB7PD;hQi=>
MCF7	NEfKcmFHfW6ldHnvckBie3OjeR?=	M1T5TVUhfU1?	MXGyOEBpenN?	MVrBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYXzwbIEhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCFRFO2JI1TVkFiZYjwdoV{e2mxbjDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCTSVH6c4whemWjZ3XueEBj[XOnZDDSWE1yWEOUIHHuZYx6e2m\|	M3iz[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe4OlA6Lz5\|MEC3PFYxQTxxYU6=
MCF7	Mk\XSpVv[3Srb36gZZN{[Xl?	Mkf0OUB2VQ>?	NWG4TWcxOjRiaILz	MYjBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYXzwbIEhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iCHMl[xJI1TVkFiZYjwdoV{e2mxbjDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCTSVH6c4whemWjZ3XueEBj[XOnZDDSWE1yWEOUIHHuZYx6e2m\|	MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{i2NFkoRjNyMEe4OlA6RC:jPh?=
MCF7	M1X2XWZ2dmO2aX;uJIF{e2G7	NE\BdYw2KHWP	M4XY[VI1KGi{cx?=	NEizU2lCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFXSZYxxcGFiaX6gbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDNT2k3PyCvUl7BJIV5eHKnc4Ppc44h[XRiNTD1UUBi\nSncjCyOEBpenNiYomgVWlCgm:uIILlZYdmdnRiYnHz[YQhWlRvcWDDVkBidmGueYPpdy=>	NFvHdIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3PFYxQSd-M{CwO\|g3ODl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / p-MEK / MEK1 / MEK2 / p21 / Cyclin D1 ; PubMed: 26163823 Cell Signal LNCaP-Raf:ER cells were treated with increasing doses of 4-hydroxytamoxifen for 2 days. The bottom panel indicates densitometry of MEK1 and MEK2 signals. Data (mean ± standard error) are from two independent experiments. Pearson’s r = 0.823 for MEK1 and −0.673 for MEK2.	26163823
Growth inhibition assay	Cell viability; PubMed: 26014809 Eur J Nutr Dose-dependent effect of 4-hydroxytamoxifen on survival of T47D, MCF-7 and BT-474 cell lines after 96 h of treatment. Control samples were treated with appropriate concentrations of DMSO. Viability was assayed by MTT method.	26014809

Protocol

Cell Research: ^[1]	- Collapse Cell lines: Adult Rat and Mouse Cardiac Myocytes Concentrations: 0, 0.5, 1, 3, 5, and 10 µM Incubation Time: 15-45 min Method: For sarcomere length measurements, cells are covered in Tyrode’s containing 4OHT, allowed to reach 36 ± 1°C, and then stimulated at 0.2 Hz. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Sprague-Dawley rats Dosages: 21 mg/kg, 54 μmol/kg Administration: oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	77 mg/mL (198.7 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download 4-Hydroxytamoxifen (Afimoxifene) SDF

Molecular Weight	387.51
Formula	C₂₆H₂₉NO₂
CAS No.	68392-35-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Afimoxifene
Smiles	CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03199963	Terminated	Drug: 4-OH tamoxifen\|Drug: Placebo	Mammographic Breast Density	BHR Pharma LLC	August 21 2017	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Estrogen/progestogen Receptor Signaling Pathway Map

Related Estrogen/progestogen Receptor Products

Licochalcone A ^New

Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.
Endoxifen HCl ^New

Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
Sacubitril/valsartan (LCZ696) ^New

Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Fulvestrant (ICI-182780)

Fulvestrant (ICI-182780, ZD 9238, ZM 182780) is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
Tamoxifen (ICI 46474) Citrate

Tamoxifen Citrate (ICI 46474) is a selective estrogen receptor modulator (SERM). Tamoxifen Citrate is also a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen induces apoptosis and autophagy.
Mifepristone (RU486)

Mifepristone (RU486, C-1073, RU 38486, Mifegyne) is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.

Features:Mifepristone is the first approved medication for patients with endogenous cushing's syndrome.
Raloxifene HCl

Raloxifene (LY156758, Keoxifene) HCl a selective and orally active estrogen receptor modulator (SERM), which inhibits human cytosolic aldehyde oxidase-catalyzed phthalazine oxidation activity with IC50 of 5.7 nM.

Features:Raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk.
Estradiol

Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.
Toremifene Citrate (NK 622)

Toremifene Citrate (NK 622, NSC 613680) is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.
Progesterone (NSC 9704)

Progesterone (NSC 9704, NSC 64377, Pregn-4-ene-3,20-dione) is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species. A potent agonist of the nuclear progesterone receptor (nPR) with Kd of 1 nM; An agonist of the membrane progesterone receptors(mPRs); An antagonist of the σ1 receptor.

Choose Your Country or Region

By Signaling Pathways

By product type

4-Hydroxytamoxifen (Afimoxifene)